Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, USA; 2Johnson & Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, US
Список исп. литературыСкрыть список 1. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. American Psychiatric Association, Washington. DC 2000. 2. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiat 1989; 154: 672–6. 3. Boom S, Thyssen A, Crauwels H et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009; 47: 606–16. 4. Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71–93. 5. Canuso CM, Youssef EA, Bossie CA et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008; 23: 209–15. 6. Canuso CM, Grinspan A, Kalali A et al. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol 2010; 25: 155–64. 7. Citrome L. Paliperidone palmitate: review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010; 64: 216–39. 8. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiat 2003; 64: 18–23. 9. Gopal S, Gassmann-Mayer C, Palumbo J et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010; 26: 377–87. 10. Gopal S, Hough DW, Xu H et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010; 25: 247–56. 11. Guy W. ECDEU Assessment Manual for Psychopharmacology. Clin Glob Impress 1976; 218–22. 12. Guy W. ECDEU Assessment Manual for Psychopharmacology revised 1976. Abnormal Involuntary Movement Scale [AIMS]. National Institute of Mental Health, Rockville. MD 1976; p. 534–7. 13. Hough D, Gopal S, Vijapurkar U et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010; 116: 107–17. 14. Kane JM, Carcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiat 2009; 195: 63–7. 15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76. 16. Kramer M, Litman R, Hough D et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010; 13: 635–47. 17. Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23. 18. Lindenmayer JP, Liu-Seifert H, Kulkarni PM et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiat 2009; 70: 990–6. 19. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiat 1997; 58: 538–46. 20. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiat 2006; 67 (Suppl. 5): 15–8. 21. Morosini PL, Magliano L, Brambilla L et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiat Scand 2000; 101: 323–9. 22. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiat Scand 2007; 115: 260–7. 23. Novick D, Haro JM, Suarez D et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiat Res 2010; 176: 109–13. 24. Pandina GJ, Lindenmayer JP, Lull J et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010; 30: 235–44. 25. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel oncemonthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinetic 2009; 48: 585–600. 26. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiat Scand 1970; 212: 11–9. 27. Velligan DI, Weiden PJ, Sajatovic M et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiat 2009; 70: 1–46. 28. Vermeir M, Naessens I, Remmerie B et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008; 36: 769–79. 29. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiat Serv 2004; 55: 886–91.